DANIELLE MCFADDEN: Open Payments
NPI 1215607122 · NEWBURGH, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,144 in 100 payments from 16 companies in 2025. Trend: 2023 $1,541 · 2024 $1,886 · 2025 $2,144
Food & beverage: $2,049Education: $95
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 22 | $457 |
| GlaxoSmithKline, LLC. | 24 | $408 |
| Viatris Specialty LLC | 11 | $312 |
| Regeneron Healthcare Solutions, Inc. | 10 | $276 |
| GENZYME CORPORATION | 9 | $158 |
| Insmed, Inc. | 7 | $118 |
| United Therapeutics Corporation | 4 | $88 |
| Verona Pharma, Inc. | 2 | $68 |
| Grifols USA, LLC | 2 | $49 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $48 |
Products named: DUPIXENT, TRELEGY ELLIPTA, YUPELRI, FASENRA, BREZTRI, Arikayce, NUCALA, Tyvaso.
Industry payments across IN — which companies pay providers there.
